Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has clinical diagnosis of Systemic Lupus Erythematosus (SLE) at least 24 weeks prior to Screening, meeting at least 4 of the 11 revised Criteria for Classification of SLE according to the 1997 Update of the 1982 American College of Rheumatology (ACR) OR meeting at least 4 of the 2012 SLICC classification criteria, including at least 1 clinical criterion and 1 immunologic criterion.~* At Screening, must have at least one of the following:~  * antinuclear antibody (ANA)+ (titer ≥ 1:80)~ * anti-dsDNA+~ * anti-Smith+~* SLEDAI-2K (SLE Disease Activity Index) ≥ 6 despite background therapy as reported and independently adjudicated (clinical score ≥ 4, excluding lupus headache and/or organic brain syndrome) at Screening:~  * If 4 points of the required entry points are for arthritis, there must also be a minimum of 3 tender and 3 swollen joints.~ * If participant has rash and Principal Investigator (PI) considers it to be attributable to SLE, participant must consent to skin photograph collection for adjudication.~ * Score must be re-confirmed at the Baseline visit.~* Physician's Global Assessment (PhGA) ≥ 1 during screening period.~* Must be on background treatment, stable for 30 days prior to Baseline and throughout the study with antimalarial(s), prednisone (or prednisone equivalent) (≤ 20 mg), azathioprine (≤ 150 mg), mycophenolate (\<2 g), leflunomide (≤ 20 mg), cyclosporine, tacrolimus, and/or methotrexate (MTX) (≤ 20 mg).~  * No combinations of the above with immunomodulators other than prednisone (or equivalents) and antimalarials.~Exclusion Criteria:~- Participant using intravenous (IV) or intramuscular (IM) corticosteroids greater than or equal to a 40 mg prednisone-equivalent bolus within 30 days of planned randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Elsubrutinib placebo/upadacitinib placebo (Type: PLACEBO_COMPARATOR): Placebo capsule for elsubrutinib once a day by mouth for up to 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for up to 48 weeks
- ABBV-599 High Dose (Elsubrutinib 60 mg/upadacitinib 30 mg) (Type: EXPERIMENTAL): 60 mg elsubrutinib capsule once a day by mouth for up to 48 weeks; 30 mg upadacitinib film-coated tablet once a day by mouth for up to 48 weeks
- Elsubrutinib placebo/upadacitinib 30 mg (Type: EXPERIMENTAL): Placebo capsule for elsubrutinib once a day by mouth for up to 48 weeks; 30 mg upadacitinib film-coated tablet once a day by mouth for up to 48 weeks
- ABBV-599 Low Dose (Elsubrutinib 60 mg/upadacitinib 15 mg) (Type: EXPERIMENTAL): 60 mg elsubrutinib capsule once a day by mouth for up to 24 weeks; 15 mg upadacitinib film-coated tablet once a day by mouth for up to 24 weeks
- Elsubrutinib 60 mg/upadacitinib placebo (Type: EXPERIMENTAL): 60 mg elsubrutinib capsule once a day by mouth for up to 24 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for up to 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).